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Summary. Background and Objective. Prostate cancer is one of the most commonly diagnosed 
malignancy affecting men in Latvia. The aim of this study was to evaluate the epidemiological fea-
tures and molecular basis of hereditary prostate cancer in Latvia.
Material and Methods. A total of 1217 newly diagnosed prostate cancer patients were recruited 
in our study. Data were analyzed according to clinical diagnostic criteria for hereditary prostate 
cancer. Molecular testing for the founder mutation 657del5 of the NBS1 gene was performed for 
the first 280 prostate cancer patients and 173 control cases, and for the founder mutations 300T/G, 
4153delA, and 5382insC of the BRCA1 gene for 112 prostate cancer patients with a history of 
breast or ovarian cancer in their families.
Results. Of the 1217 families, 14 (1.2%; 95% CI, 0.7%–1.9%) matched clinical diagnostic 
criteria for definitive hereditary prostate cancer, and of the 1217 families, 196 (16.1%; 95% CI, 
14.1%–18.3%) for suspected hereditary prostate cancer. The founder mutation of the NBS1 gene 
was detected in 1 (0.4%, 95% CI, 0.1%–2.0%) of the 280 cases in the prostate cancer group and 
in 1 (0.6%; 95% CI, 0.1%–3.2%) of the 173 cases in the control group. The mutation 5382insC of 
the BRCA1 gene was detected in 2 (1.8%; 95% CI, 0.5%–6.3%) of the 112 cases analyzed in the 
prostate cancer group. No other BRCA1 founder mutations were detected.
Conclusions. Our study did not reveal predisposition genes for hereditary prostate cancer as the 
founder mutations of the BRCA1 and NBS1 genes are rarely detected in Latvia, but showed the 
importance of evaluation risk individually as a positive family history of cancer was associated with 
the earlier onset of prostate cancer. 
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Introduction
Prostate cancer is one of the most common-
ly diagnosed cancers among men worldwide with 
a signifi cant difference in incidence rates among 
the world’s geographic regions; during the past 15 
years, it has become an important concern of public 
health (1). The highest incidence has been reported 
in the Scandinavian countries, with an intermedi-
ate incidence being reported in the United States 
and the United Kingdom and the lowest being in 
the Far East, especially in China and Japan (2). In 
the United States and Sweden, prostate cancer is the 
most common cancer of all malignancies, ahead of 
lung cancer (3). In 2008, around 338 000 men were 
diagnosed with prostate cancer in Europe (4). The 
lowest European incidence rates are in Southern 
and Eastern Europe, and the highest rates are found 
in Northern and Western Europe (Fig. 1). Prostate 
cancer is the second most commonly diagnosed ma-
lignancy in men after lung cancer in Latvia (Fig. 2). 
The prevalence and incidence rates for prostate 
cancer in Latvia are increasing year by year: from 
1813 cases in 2000 to 4850 cases in 2010 and from 
522 cases in 2000 to 855 cases in 2010, respectively 
(Fig. 3). Despite a wide range of diagnostic meas-
ures and aggressive treatment, the mortality rate 
from prostate cancer has not changed signifi cantly 
and is one of the major causes of death among men 
in Latvia.
Progression of prostate cancer is a complex in-
teraction of molecular, environmental, and possibly 
social factors (5). Family cancer history is an impor-
tant screening tool for identifi cation of high-risk pa-
tients groups with inherited cancer. It is important 
to differentiate molecular and environmental risk 
factors affecting the progression of prostate cancer, 
and family cancer history is a helpful tool that cap-
tures some of these risk aspects (6). Although envi-
ronment, diet, lifestyle, sex hormones, and genetic 
predisposition of individuals are all risk factors for 
prostate cancer, a positive family history of prostate 
cancer is the most important clinical risk factor. Ac-
cording to a Nordic study of twins, hereditary fac-
tors play a much greater role in the etiology of pros-
tate cancer than in that of any other malignancy (7). 
Many studies on several alleles indicate the con-
ferring of dominantly inherited susceptibility for 
prostate cancer with high penetrance, causing mul-
tiple cases of prostate cancer in a family. However, 
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Fig. 2. Ten most common malignancies among men during 2005–2009 































the genes involved in predisposition to hereditary 
prostate cancer have not been identifi ed. This may 
be due to the fact that several genes with small-to-
moderate effect are involved in carcinogenesis. Epi-
demiologically prostate cancer can be divided into 
hereditary and sporadic forms (8), but it is not pos-
sible to distinguish these two groups at the molecu-
lar level. Although possible inherited prostate can-
cer susceptibility genes, such as BRCA1, BRCA2, 
ELAC2, RNASEL, MSR1, NBS1, and CHEK2, 
have been identifi ed in some families, the propor-
tion of cases of hereditary prostate cancer attribut-
able to germ line mutations in these loci is small (9–
12). Many studies have not proven the role of these 
genes in hereditary prostate cancer (13). Mutations 
of these candidate genes have also been identifi ed in 
sporadic prostate cancer. Because prostate cancer is 
a common cancer, it may be diffi cult to distinguish 
the clustering of sporadic prostate cancers within 
families from true hereditary prostate cancer.
Genome research is a complex and time-con-
suming process. Revealing the most frequent muta-
tions in the Latvian population could considerably 
improve the presymptomatic diagnosis of prostate 
cancer. As no detailed studies have been done in 
Latvia, the aim of the present study was to evaluate 
the epidemiological features and molecular basis 
of hereditary prostate cancer in Latvia, and to con-
sider the clinical implications of our fi ndings.
Material and Methods
This was a prospective study involving 1217 pa-
tients with newly diagnosed prostate cancer from all 
regions of Latvia identifi ed at the largest oncology 
hospitals. All patients for our study were selected 
and identifi ed from November 2003 to March 2011. 
All patients were enrolled in the study regardless of 
TNM stage, Gleason’s score, ethnicity, or health status. 
Data on clinical characteristics including age at 
diagnosis, individual nationality, and family can-
cer history were collected using a standardized 
questionnaire previously tested in hospital- and 
population-based screening (14, 15). Prostate can-
cer patients were asked if their blood relatives had 
had any malignancy. Further, information on can-
cer localization, age of cancer diagnosis, and age at 
death, if applicable, was collected. Completed ques-
tionnaires were analyzed separately depending on 
positive (at least one malignancy of any localization 
among blood relatives) or negative (no malignancy 
among blood relatives) data of family cancer history. 
Table 1 summarizes the characteristics of patients 
with prostate cancer by age groups in association 
with a family history of prostate cancer. Family can-
cer histories matching hereditary cancer syndrome 
were analyzed according to the clinical diagnostic 
criteria of hereditary prostate cancer (Table 2). All 
patients were invited for additional consultation 
and were offered molecular diagnostics. If patients 
agreed, peripheral venous blood samples were col-
lected. Molecular examination was performed for 
the fi rst 280 prostate cancer patients and 173 control 
cases for the founder mutation 657del5 of the NBS1 
gene and 68 prostate cancer patients for the founder 
mutations 300T/G, 4153delA, and 5382insC of the 
BRCA1 gene if any case of breast or ovarian cancer 
was observed in their family. Blood samples of the 
control group were collected from the clamped dis-
tal part of the umbilical cord in consecutive anony-
mous newborns.
Statistical data analysis was carried out with the 
CIA (DOS program Confi dence Interval Analysis) 
Fig. 3. Prostate cancer prevalence, incidence, and mortality rates in absolute numbers
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software (16). The study was approved by the Drug 
and Pharmaceutical Product Research Ethics Com-
mittee of Latvia. Written informed consent was ob-
tained from all the patients.
Results 
In total, 1217 family cancer histories were an-
alyzed; 640 families (52.6%; 95% CI, 49.8% to 
55.4%) were found to have a positive family his-
tory of cancer, and 577 families (47.4%; 95% CI, 
44.6% to 50.2%) had no family cancer history. Our 
series showed the relationship between family can-
cer history and age at the onset of prostate cancer: 
individuals with a positive family history of cancer 
were younger at the onset of prostate cancer than 
individuals with a negative family history of cancer 
(Fig. 4).
Of the 1217 families, 14 (1.2%; 95% CI, 0.7% to 
1.9%) matched the defi nitive clinical diagnostic cri-
teria of hereditary prostate cancer, and of the 1217 
families, 196 (16.1%; 95%, CI, 14.1% to 18.3%) 
matched suspected clinical diagnostic criteria of 
hereditary prostate cancer. In our study, the me-
dian age at diagnosis was 64.1 years (range, 51–74 
years) in the defi nitive hereditary prostate cancer 
group and 58.5 years (range, 42–85 years) in the 
suspected hereditary prostate cancer group. At least 
1 other cancer was found among blood relatives in 
9 (64.3%; 95% CI, 38.8% to 83.7%) of the 14 fam-
ily cancer histories of the defi nitive hereditary pros-
tate cancer group and in 87 (44.4%; 95% CI, 37.6% 
to 51.4%) of the 196 family cancer histories of the 
suspected hereditary prostate cancer group. A more 
detailed summary of characteristics of the most fre-
quently diagnosed malignancies among blood rela-
tives is provided in Figs. 5 and 6.
Equally, a founder mutation of the NBS1 gene 
was detected in 1 (0.4%; 95% CI, 0.1% to 2.0%) of 
the 280 cases in the prostate cancer group and in 1 
(0.6%; 95% CI, 0.1% to 3.2%) of the 173 cases in 
the control group. The individual from the prostate 
cancer group was a 68-year-old male with a negative 
family history of cancer. As the control group data 
were anonymous, no data concerning family cancer 
history were available.
Of the 112 samples analyzed in the prostate can-
cer group, 2 cases (1.8%; 95% CI, 0.5% to 6.3%) of 

















































Total 1217 640 (52.6) 577 (47.4)
Table 1. Characteristics of Prostate Cancer Cases by Age 
Groups in Association With Family Cancer History 
at Age of Diagnosis 
Table 2. Clinical Diagnostic Criteria of Hereditary 
Prostate Cancer




1) At least 3 blood relatives 
with prostate cancer at any age 
or
1) Two blood relatives with 
prostate cancer at any age 
or
2) Two blood relatives with 
prostate cancer diagnosed be-
fore the age of 55 years 
in both of them
2) A case of prostate cancer 
diagnosed before the age 
of 55 years
Fig. 4. Percentage distribution of cases with positive and negative family cancer history (FCH) by age 
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tifi ed. The fi rst individual was a 66-year-old male 
with a positive family history of cancer (2 sisters 
with breast cancer and father’s brother with gastric 
cancer). The second individual was a 70-year-old 
male from the family matching the clinical diag-
nostic criteria of hereditary breast cancer. No other 
BRCA1 founder mutations were detected.
Discussion 
Although it is thought that 5% to 10% of prostate 
cancer cases are hereditary (17), our study revealed 
a relatively low proportion of families with defi ni-
tive inheritance and high proportion of families with 
suspected inheritance (1.3% vs. 14.1%). As clinical 
defi nition of hereditary prostate cancer is based on 
the data of family cancer history, any missing part 
of information is critical. Therefore, any family with 
no other malignancies among relatives should be 
carefully evaluated and considered as incomplete as 
data could be missing due to loss of contact during 
wartime, deportation, and migration in the middle 
of the 20th century in Latvia.
Except for younger age at diagnosis, no pheno-
typic features have been clearly associated with he-
reditary prostate cancer (18). Our data did not reveal 
a signifi cant difference in the median age at diagno-
sis of prostate cancer comparing the defi nitive and 
suspected hereditary pros tate cancer groups. 
The molecular pathology of prostate cancer is 
complex; not only multiple genes are involved in 
its pathogenesis, but additional environmental fac-
tors as well (5). The BRCA1, BRCA2, NBS1, and 
CHEK2 genes have been only recently identifi ed as 
possible prostate cancer susceptibility genes. ELAC2 
was the fi rst hereditary prostate cancer susceptibil-
ity gene identifi ed, and subsequent studies have not 
confi rmed the evidence for its role in prostate can-
cer (19). Therefore, it is not possible to comment on 
the importance of these genes in hereditary prostate 
cancer until additional confi rmatory studies have 
been performed. 
A study from southern Sweden (n=356) revealed 
that 15% of patients with prostate cancer had at least 
1 case of prostate cancer among their brothers or 
fathers. Based on the family history, 3.1% were 
classifi ed as having hereditary prostate cancer. Fur-
Fig. 5. Percentage distribution of the most frequently diagnosed malignancies among blood relatives
in the defi nitive hereditary prostate cancer group
Fig. 6. Percentage distribution of the most frequently diagnosed malignancies among blood relatives 
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thermore, this proportion was signifi cantly higher 
among patients diagnosed before the age of 60 years 
than among older patients (7.1% vs. 2.2%) (20). 
A systematic genealogy study from France 
(n=691) confi rmed the data of earlier studies, re-
vealing a 3.6% prevalence of hereditary forms of 
prostate cancer. Analysis of the results according 
to the age at diagnosis of prostate cancer showed a 
higher incidence of hereditary forms occurring at 
younger age, i.e., before the age of 65 years. Similar-
ly, the study confi rmed the earlier onset of prostate 
cancer in patients with a genetic predisposition (21).
Both positive and negative studies have been 
published showing the increased risk of prostate 
cancer in BRCA1 and BRCA2 mutation carriers 
(22–24). To establish the infl uence of the BRCA1 
gene, 1793 men with prostate cancer and 4570 con-
trols were genotyped for founder mutations (C61G, 
4153delA, and 5382insC) in Poland. The results 
showed a higher frequency of the 4153delA muta-
tion in prostate cancer cases (0.22%) than controls 
(0.04%). Data suggest that the 5382insC mutation is 
unlikely to be pathogenic for prostate cancer in the 
Polish population as it was more frequently present 
in the control population than in the prostate can-
cer group (25). In our study, of the 68 individuals 
analyzed, only 1 case was found to carry the muta-
tion 5382insC in the BRCA1 gene. This may be 
explained by the high proportion of the Slavic pop-
ulation in Latvia. Although there are data confi rm-
ing a more aggressive prostate cancer phenotype for 
BRCA1 and BRCA2 mutation carriers, it was not 
considered for analysis in our study as the number 
of cases was limited (26, 27).
A recent study has reported that BRCA2 carriers 
with prostate cancer have a poorer survival rate than 
noncarrier with prostate cancer. In this study, the 
survival rate of men with the BRCA2 mutation and 
prostate cancer (n=182) was compared with that of 
men with the BRCA1 mutation and prostate cancer 
(n=119). The median survival rate from diagnosis 
was 4.0 years for men with the BRCA2 mutation 
and 8.0 years for men with the BRCA1 mutation, 
with a highly signifi cant difference (28).
The frequency of the NBS1 gene mutation in 
the German population is 1 per 866 people (29). In 
comparison, a remarkably high carrier frequency of 
the 657del5 mutation in the NBS1 gene was detect-
ed in the Slavic populations: 1 per 154 in the Czech 
Republic, 1 per 190 in Poland, and 1 per 182 in 
Ukraine (30). Our data failed to support the involve-
ment of the NBS1 gene in our prostate cancer cases, 
as no statistically signifi cant difference between the 
prostate cancer and control groups was detected in 
Latvia (1 per 280 vs. 1 per 173). This supports pre-
vious studies and confi rms geographical and racial 
differences among populations.
Conclusions 
Increased incidence rates for prostate cancer 
in Latvia may be the result of improved detection 
and better awareness of the disease rather than a 
true increase in the prevalence of the disease. Our 
study did not reveal predisposition genes for he-
reditary prostate cancer as the founder mutations 
of the BRCA1 and NBS1 genes are rarely detected 
in Latvia. We observed a insignifi cant difference 
in the frequency of BRACA1 and NBS1 founder 
mutations between prostate cancer and the control 
group; this may be explained by geographical dif-
ferences and the relatively high proportion of mixed 
ethnic groups in Latvia. Our epidemiological series 
show a lower incidence of hereditary prostate cancer 
in Latvia compared with the data from other popu-
lations. The main reason affecting this may be an 
incomplete family cancer history due to the loss of 
contact with relatives. 
This emphasizes the importance of evaluation of 
family cancer history as individuals with a positive 
family history of cancer (at least one malignancy of 
any localization among blood relatives) have an ear-
lier onset of prostate cancer than individuals with 
a negative family history of cancer (no malignancy 
cases among blood relatives).
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